Catalyst

Slingshot members are tracking this event:

Aurinia Announces 24 Week Remission Rates From the First Seven Patients In Its Open Label Aurion Study In Lupus Nephritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AUPH

100%

Additional Information

Additional Relevant Details At 24 weeks 57% (4/7) of patients continued to be in complete remission as measured by a urinary protein creatinine ratio of ≤ 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of less than 5mg/day. Among these seven AURION patients there was a 54% mean reduction in proteinuria at 24 weeks compared to pre-treatment levels along with consistent improvements in C3, C4 and anti-DS DNA. Renal function as measured by eGFR remained stable and no new safety signals were observed. 
http://www.auriniaph...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 28, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Lupus Nephritis, Remission Rates, Aurion, Renal Function, Systemic Lupus Erythematosus, Steroid, Anti-ds Dna